<DOC>
	<DOCNO>NCT01156857</DOCNO>
	<brief_summary>This multicentre , Phase III , efficacy safety open-label study PGL4001 10mg daily 3 month , blind towards administration progestin placebo end PGL4001 treatment .</brief_summary>
	<brief_title>PGL4001 Efficacy Assessment Reduction Symptoms Due Uterine Leiomyomata</brief_title>
	<detailed_description>PGL4001 administer daily subject open-label manner control group . The three month open label treatment period follow ten day double blind treatment progestin match placebo . Subjects randomly assign progestin matching placebo arm 1:1 ratio .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Subject premenopausal woman age 18 48 year inclusive . Subject Body Mass Index ≥18 ≤40 . Subject myomatous uterus size &lt; 16 week . Subject must least one uterine myoma least 3 cm diameter size myoma large 10 cm diameter diagnose ultrasound . Subject complain strong uterine bleeding . Subject eligible hysterectomy myomectomy . Females childbearing potential practice nonhormonal method contraception . Subject history current uterus , cervix , ovarian breast cancer . Subject history endometrium hyperplasia adenocarcinoma biopsy perform within past 6 month similar lesion screen biopsy . Subject know severe coagulation disorder . Subject history treatment myoma SPRM , include ulipristal acetate . Subject abnormal hepatic function study entry .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>